Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.
Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to suppressed signals from nerves that promote bone marrow regeneration, according to scientists at the Children’s Medical Center Research Institute at UT Southwestern, published in Cancer Discovery, builds upon previous CRI research by analyzing retrospective patient data to correlate beta-blocker use with significantly worse patient outcomes.
